| Autor: |
Athanasios, Rempakos, Adamantia, Papamichail, Konstantinos, Loritis, Emmanouil, Androulakis, Nikki, Lama, Alexandros, Briasoulis |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Current Pharmaceutical Design. 29:527-534 |
| ISSN: |
1381-6128 |
| DOI: |
10.2174/1381612829666221212100114 |
| Popis: |
Abstract: Cardiac involvement is the leading cause of death in patients with cardiac amyloidosis. Early recognition is crucial as it can significantly change the course of the disease. Until now, the imaging modality of choice for diagnosing cardiac amyloidosis has been cardiac magnetic resonance imaging (CMR) with late gadolinium enhancement (LGE). LGE-CMR in patients with cardiac amyloidosis reveals characteristic LGE patterns that lead to a diagnosis while also correlating well with disease prognosis. However, LGE-CMR has numerous drawbacks that the newer CMR modality, T1 mapping, aims to improve. T1 mapping can be further subdivided into native T1 mapping, which does not require the use of contrast, and ECV measurement, which requires the use of contrast. Numerous T1 mapping techniques have been developed, each one with its own advantages and disadvantages when it comes to procedure difficulty and image quality. A literature review to identify relevant published articles was performed by two authors. This review aimed to present the value of T1 mapping in diagnosing cardiac amyloidosis, quantifying the amyloid burden, and evaluating the prognosis of patients with amyloidosis with cardiac involvement. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
